title: [Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016].
abstract: The 2015 European Guidelines on Pulmonary Hypertension did not cover only pulmonary arterial hypertension (PAH), but also other significant subgroups of pulmonary hypertension (PH). In June 2016, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany to discuss open and controversial issues surrounding the practical implementation of the European Guidelines. Several working groups were initiated, one of which was dedicated to the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). In every patient with PH of unknown cause CTEPH should be excluded. The primary treatment option is surgical pulmonary endarterectomy (PEA) in a specialized multidisciplinary CTEPH center. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. For balloon pulmonary angioplasty (BPA), there is currently only limited experience. This option - as PEA - is reserved to specialized centers with expertise for this treatment method. In addition, a brief overview is given on pulmonary artery sarcoma, since its surgical treatment is often analogous to PEA. The recommendations of this working group are summarized in the present paper.
authors.forename: H
authors.initials: H
authors.lastname: Wilkens
authors.forename: S
authors.initials: S
authors.lastname: Konstantinides
authors.forename: I
authors.initials: I
authors.lastname: Lang
authors.forename: A C
authors.initials: AC
authors.lastname: Bunck
authors.forename: M
authors.initials: M
authors.lastname: Gerges
authors.forename: F
authors.initials: F
authors.lastname: Gerhardt
authors.forename: A
authors.initials: A
authors.lastname: Grgic
authors.forename: C
authors.initials: C
authors.lastname: Grohé
authors.forename: S
authors.initials: S
authors.lastname: Guth
authors.forename: M
authors.initials: M
authors.lastname: Held
authors.forename: J
authors.initials: J
authors.lastname: Hinrichs
authors.forename: M M
authors.initials: MM
authors.lastname: Hoeper
authors.forename: W
authors.initials: W
authors.lastname: Klepetko
authors.forename: T
authors.initials: T
authors.lastname: Kramm
authors.forename: U
authors.initials: U
authors.lastname: Krüger
authors.forename: M
authors.initials: M
authors.lastname: Lankeit
authors.forename: B C
authors.initials: BC
authors.lastname: Meyer
authors.forename: K M
authors.initials: KM
authors.lastname: Olsson
authors.forename: H-J
authors.initials: HJ
authors.lastname: Schäfers
authors.forename: M
authors.initials: M
authors.lastname: Schmidt
authors.forename: H J
authors.initials: HJ
authors.lastname: Seyfarth
authors.forename: S
authors.initials: S
authors.lastname: Ulrich
authors.forename: C B
authors.initials: CB
authors.lastname: Wiedenroth
authors.forename: E
authors.initials: E
authors.lastname: Mayer
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage; D002309:Cardiology / Q000592:standards; D004359:Drug Therapy, Combination / Q000592:standards; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000592:standards; D017410:Practice Guidelines as Topic; D011655:Pulmonary Embolism / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D015272:Pulmonary Medicine / Q000592:standards*
chemical_list: D000959:Antihypertensive Agents; D005343:Fibrinolytic Agents